media – Page 541 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

OWLSTONE MEDICAL RAISES $15 MILLION USD (£11 MILLION GBP) WITH HORIZONS VENTURES AND AVIVA

SBRI Healthcare alumni and Cambridge-based Owlstone Medical has announced that it has raised $15 million (£11 million) to drive the global commercialisation of its Breath Biopsy® platform.
- Source: eahsn.org
- 527
- March 16, 2018
Breath Biopsy® platform lung cancer Market Views
Crinetics Pharmaceuticals Snags $63.5 Million in Series B Funding

Five months after its lead drug began Phase I testing San Diego-based Crinetics Pharmaceuticals Inc has secured $63.5 million in Series B financing.
- Source: biospace
- 409
- March 16, 2018
acromegaly Market Views serise
Takeda looks east for another Entyvio growth spurt

Takeda's inflammatory bowel disease treatment Entyvio has already been delivering blockbuster-plus sales, and the Japanese drugmaker sees fertile territory for more growth in the Asia-Pacific region.
- Source: fiercepharma
- 515
- March 15, 2018
bowel Company Insight Entyvio
Cancer Researck UK links with Ideaya on PARG inhibitors

Cancer Research UK is partnering with US biotech Ideaya Biosciences to develop small molecule inhibitors of Poly(ADP-ribose) glycohydrolase (PARG).
- Source: pharmatimes
- 488
- March 15, 2018
glycohydrolase inhibitor Market Views
Participants in rogue herpes vaccine research take legal action

Three people injected with an unauthorized herpes vaccine by a Southern Illinois University researcher have filed suit against his company, demanding compensation for alleged adverse side effects from the experiments.
- Source: fiercepharma
- 596
- March 15, 2018
herpes Researches vaccine
Aspirin prevents venous thromboembolism following major orthopedic surgeries, study finds

A multicentre, double-blind, randomized, controlled clinical trial of patients who underwent total hip or knee replacement surgery showed that aspirin was as effective as rivaroxaban, the standard anti-coagulation medication, at preventing post-operative venous thromboembolism (VTE).
- Source: Medicalxpress
- 441
- March 15, 2018
aspirin Researches
ROCHE TO BUY FLATIRON HEALTH FOR $1.9 BN TO EXPAND CANCER CARE

Swiss drugmaker Roche Holding AG (ROG.S) said on Thursday it would buy the rest of U.S. cancer data company Flatiron Health for $1.9 billion (1.35 billion pounds) to speed development of cancer medicines and support its efforts to price them based on how well they work.
- Source: Reuters
- 497
- March 15, 2018
cancer Market Views
FDA Grants Breakthrough Device Designation to Polyganics’ Liver and Pancreas Sealant Patch

Polyganics, a privately held medical technology company that develops, manufactures and commercializes bioresorbable medical devices, announced that the US Food and Drug Administration (FDA) has granted Polyganics’ request for Breakthrough Device designation to its Liver and Pancreas Sealant Patch. The Liver and Pancreas Sealant patch is considered a unique breakthrough in the prevention of fluid leakage after hepato-pancreato-biliary (HPB) procedures, for which currently no approved or cleared alternatives exist.
- Source: polyganics
- 652
- March 15, 2018
bioresorbable medical devices FDA New Approvals Polyganics
Patient death forces FDA to slap a hold on study using combo from Advaxis, AstraZeneca — biotech’s shares plunge

The FDA has slapped a clinical hold on a combo therapy using Advaxis’$ADXS axalimogene filolisbac along with AstraZeneca’s approved PD-L1 Imfinzi following the death of a patient in their Phase I/II trial.
- Source: endpts
- 622
- March 15, 2018
AstraZeneca cervical cancer Company Insight FDA
IMMUTEP ENTERS INTO CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH MSD

Immutep Limited (ASX:IMM) (IMMP) (“Immutep” or the “Company”) has announced that it has entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada), through a subsidiary, to evaluate the combination of Immutep’s lead immunotherapy product candidate eftilagimod alpha (“efti” or “IMP321”) with MSD's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a new clinical trial that will evaluate the combination in several different solid tumours.
- Source: finance.yahoo
- 627
- March 14, 2018
Company Insight immunotherapy keytruda

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.